70 related articles for article (PubMed ID: 25919760)
41. 2011 update of the drug resistance mutations in HIV-1.
Johnson VA; Calvez V; Günthard HF; Paredes R; Pillay D; Shafer R; Wensing AM; Richman DD
Top Antivir Med; 2011 Nov; 19(4):156-64. PubMed ID: 22156218
[TBL] [Abstract][Full Text] [Related]
42. It is time to consider third-line options in antiretroviral-experienced paediatric patients?
Zyl GU; Rabie H; Nuttall JJ; Cotton MF
J Int AIDS Soc; 2011 Nov; 14():55. PubMed ID: 22085598
[TBL] [Abstract][Full Text] [Related]
43. Human leukocyte antigen class I (A, B, C) and II (DRB1) diversity in the black and Caucasian South African population.
Paximadis M; Mathebula TY; Gentle NL; Vardas E; Colvin M; Gray CM; Tiemessen CT; Puren A
Hum Immunol; 2012 Jan; 73(1):80-92. PubMed ID: 22074999
[TBL] [Abstract][Full Text] [Related]
44. Molecular Basis for Drug Resistance in HIV-1 Protease.
Ali A; Bandaranayake RM; Cai Y; King NM; Kolli M; Mittal S; Murzycki JF; Nalam MNL; Nalivaika EA; Özen A; Prabu-Jeyabalan MM; Thayer K; Schiffer CA
Viruses; 2010 Nov; 2(11):2509-2535. PubMed ID: 21994628
[TBL] [Abstract][Full Text] [Related]
45. HIV-1 adaptation to NK-cell-mediated immune pressure.
Alter G; Heckerman D; Schneidewind A; Fadda L; Kadie CM; Carlson JM; Oniangue-Ndza C; Martin M; Li B; Khakoo SI; Carrington M; Allen TM; Altfeld M
Nature; 2011 Aug; 476(7358):96-100. PubMed ID: 21814282
[TBL] [Abstract][Full Text] [Related]
46. Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa.
Wallis CL; Mellors JW; Venter WD; Sanne I; Stevens W
AIDS Res Treat; 2011; 2011():769627. PubMed ID: 21490784
[TBL] [Abstract][Full Text] [Related]
47. Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa.
Taylor BS; Hunt G; Abrams EJ; Coovadia A; Meyers T; Sherman G; Strehlau R; Morris L; Kuhn L
AIDS Res Hum Retroviruses; 2011 Sep; 27(9):945-56. PubMed ID: 21345162
[TBL] [Abstract][Full Text] [Related]
48. Three residues in HIV-1 matrix contribute to protease inhibitor susceptibility and replication capacity.
Parry CM; Kolli M; Myers RE; Cane PA; Schiffer C; Pillay D
Antimicrob Agents Chemother; 2011 Mar; 55(3):1106-13. PubMed ID: 21149628
[TBL] [Abstract][Full Text] [Related]
49. Antiretroviral treatment for children with peripartum nevirapine exposure.
Palumbo P; Lindsey JC; Hughes MD; Cotton MF; Bobat R; Meyers T; Bwakura-Dangarembizi M; Chi BH; Musoke P; Kamthunzi P; Schimana W; Purdue L; Eshleman SH; Abrams EJ; Millar L; Petzold E; Mofenson LM; Jean-Philippe P; Violari A
N Engl J Med; 2010 Oct; 363(16):1510-20. PubMed ID: 20942667
[TBL] [Abstract][Full Text] [Related]
50. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
Coovadia A; Abrams EJ; Stehlau R; Meyers T; Martens L; Sherman G; Hunt G; Hu CC; Tsai WY; Morris L; Kuhn L
JAMA; 2010 Sep; 304(10):1082-90. PubMed ID: 20823434
[TBL] [Abstract][Full Text] [Related]
51. Initial response to protease-inhibitor-based antiretroviral therapy among children less than 2 years of age in South Africa: effect of cotreatment for tuberculosis.
Reitz C; Coovadia A; Ko S; Meyers T; Strehlau R; Sherman G; Kuhn L; Abrams EJ
J Infect Dis; 2010 Apr; 201(8):1121-31. PubMed ID: 20214476
[TBL] [Abstract][Full Text] [Related]
52. Protease inhibitor resistance in South African children with virologic failure.
van Zyl GU; van der Merwe L; Claassen M; Cotton MF; Rabie H; Prozesky HW; Preiser W
Pediatr Infect Dis J; 2009 Dec; 28(12):1125-7. PubMed ID: 19779394
[TBL] [Abstract][Full Text] [Related]
53. HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins.
Brumme ZL; John M; Carlson JM; Brumme CJ; Chan D; Brockman MA; Swenson LC; Tao I; Szeto S; Rosato P; Sela J; Kadie CM; Frahm N; Brander C; Haas DW; Riddler SA; Haubrich R; Walker BD; Harrigan PR; Heckerman D; Mallal S
PLoS One; 2009 Aug; 4(8):e6687. PubMed ID: 19690614
[TBL] [Abstract][Full Text] [Related]
54. Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1.
Parry CM; Kohli A; Boinett CJ; Towers GJ; McCormick AL; Pillay D
J Virol; 2009 Sep; 83(18):9094-101. PubMed ID: 19587031
[TBL] [Abstract][Full Text] [Related]
55. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.
Dam E; Quercia R; Glass B; Descamps D; Launay O; Duval X; Kräusslich HG; Hance AJ; Clavel F;
PLoS Pathog; 2009 Mar; 5(3):e1000345. PubMed ID: 19300491
[TBL] [Abstract][Full Text] [Related]
56. Early initiation of lopinavir/ritonavir in infants less than 6 weeks of age: pharmacokinetics and 24-week safety and efficacy.
Chadwick EG; Pinto J; Yogev R; Alvero CG; Hughes MD; Palumbo P; Robbins B; Hazra R; Serchuck L; Heckman BE; Purdue L; Browning R; Luzuriaga K; Rodman J; Capparelli E;
Pediatr Infect Dis J; 2009 Mar; 28(3):215-9. PubMed ID: 19209098
[TBL] [Abstract][Full Text] [Related]
57. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Koh Y; Das D; Leschenko S; Nakata H; Ogata-Aoki H; Amano M; Nakayama M; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2009 Mar; 53(3):997-1006. PubMed ID: 18955518
[TBL] [Abstract][Full Text] [Related]
58. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.
Ren Y; Nuttall JJ; Egbers C; Eley BS; Meyers TM; Smith PJ; Maartens G; McIlleron HM
J Acquir Immune Defic Syndr; 2008 Apr; 47(5):566-9. PubMed ID: 18197120
[TBL] [Abstract][Full Text] [Related]
59. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
[TBL] [Abstract][Full Text] [Related]
60. Not so different after all: a comparison of methods for detecting amino acid sites under selection.
Kosakovsky Pond SL; Frost SD
Mol Biol Evol; 2005 May; 22(5):1208-22. PubMed ID: 15703242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
